Pereira, P.S., et al. Safety of the M72/AS01 Tuberculosis Vaccine in People Living With HIV: A Systematic Review and Meta-Analysis. Open Forum Infect Dis, 2026 Sep 21, 13(9):ofag578. PMID: 42787558

 In Saponin-Related Publications, Scientific Papers

Tuberculosis (TB) remains a major global health crisis, particularly for people living with HIV (PLHIV), who face heightened susceptibility and a lack of safe, effective preventive vaccines. This systematic review and meta-analysis is critical for those interested in vaccine adjuvants because it specifically investigates the safety of the M72/AS01 TB vaccine in this vulnerable population.

The AS01 adjuvant system is known for its strong innate immune activation. Given that HIV causes immune dysregulation even in individuals on antiretroviral therapy (ART), assessing the safety of such a potent adjuvant in PLHIV is essential, as its effects cannot be simply extrapolated from HIV-negative populations.

The findings demonstrate a favorable safety profile for M72/AS01 in immunologically stable, virologically suppressed adults living with HIV on ART. While the AS01-adjuvanted vaccine did increase the risk of predominantly mild-to-moderate, self-limited solicited local and systemic adverse events like pain, swelling, headache, myalgia, and fever, there was no observed increase in unsolicited adverse events or vaccine-related serious adverse events. This outcome is significant, as it supports the safe use of an AS01-adjuvanted vaccine in this immunocompromised group, thereby justifying further studies to evaluate its efficacy for TB prevention.

Click here to access the full scientific paper.

[arrow_forms id=’3298′]
Recent Posts

Start typing and press Enter to search